Maneka Mirchandaney
Stock Analyst at Evercore ISI Group
(0.31)
# 4,073
Out of 4,761 analysts
7
Total ratings
28.57%
Success rate
-28.86%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Maneka Mirchandaney
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRNX Crinetics Pharmaceuticals | Maintains: Outperform | $41 → $48 | $37.46 | +28.14% | 2 | Sep 11, 2023 | |
| INKT MiNK Therapeutics | Maintains: Outperform | $4 → $3 | $10.10 | -70.30% | 2 | Mar 22, 2023 | |
| INCY Incyte | Downgrades: In-Line | $90 → $78 | $72.11 | +8.17% | 1 | Aug 3, 2022 | |
| VRDN Viridian Therapeutics | Initiates: Outperform | $40 | $16.27 | +145.85% | 1 | Oct 12, 2021 | |
| HOWL Werewolf Therapeutics | Initiates: Outperform | $23 | $1.38 | +1,566.67% | 1 | May 25, 2021 |
Crinetics Pharmaceuticals
Sep 11, 2023
Maintains: Outperform
Price Target: $41 → $48
Current: $37.46
Upside: +28.14%
MiNK Therapeutics
Mar 22, 2023
Maintains: Outperform
Price Target: $4 → $3
Current: $10.10
Upside: -70.30%
Incyte
Aug 3, 2022
Downgrades: In-Line
Price Target: $90 → $78
Current: $72.11
Upside: +8.17%
Viridian Therapeutics
Oct 12, 2021
Initiates: Outperform
Price Target: $40
Current: $16.27
Upside: +145.85%
Werewolf Therapeutics
May 25, 2021
Initiates: Outperform
Price Target: $23
Current: $1.38
Upside: +1,566.67%